BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 1,292 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,292 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $276.26, for a total value of $356,927.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The stock was sold at an average price of $266.76, for a total value of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total value of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total value of $399,745.08.

BeOne Medicines Trading Down 0.6%

NASDAQ ONC opened at $275.34 on Friday. The company has a market cap of $30.21 billion, a P/E ratio of 61.60 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $239.25 and a 12 month high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a 50-day moving average of $292.55 and a 200-day moving average of $310.42.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. As a group, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently modified their holdings of the stock. Mariner LLC raised its holdings in shares of BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after buying an additional 32 shares during the period. Signaturefd LLC grew its position in BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after acquiring an additional 39 shares in the last quarter. CWM LLC raised its stake in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Benjamin Edwards Inc. raised its stake in shares of BeOne Medicines by 8.0% during the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

ONC has been the subject of several research reports. Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Truist Financial reissued a “buy” rating and set a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Leerink Partners raised their price objective on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Finally, Barclays boosted their target price on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.